Cero Therapeutics Holdings Inc., a Delaware-based company, announced on June 11, 2025, that it received a notification from Nasdaq regarding a failure to meet the minimum bid price requirement for its common stock. For 30 consecutive business days, the company's stock price remained below the $1.00 per share threshold mandated by Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. Cero Therapeutics is not eligible for a compliance period due to previous reverse stock splits. In response, the company has requested a hearing before the Nasdaq Hearings Panel to contest the delisting decision. Additionally, the company executed a reverse stock split, effective June 13, 2025, at a 1-for-20 ratio, raising the stock price to $7.31 per share. However, there is no guarantee that this price level will be maintained or that the appeal will succeed, leaving the company's Nasdaq listing status uncertain.